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Interleukin-1b (IL-1b) is overproduced in human and rodent epileptogenic tissue and it exacerbates seizures upon
brain application in rodents. Moreover, pharmacological prevention of IL-1bendogenous synthesis, or IL-1 recep-
tor blockade, mediates powerful anticonvulsive actions indicating a significant role of this cytokine in ictogen-
esis. The molecular mechanisms of the proconvulsive actions of IL-1b are not known. We show here that EEG
seizures induced by intrahippocampal injection of kainic acid in C57BL6 adult mice were increased by 2-fold on
average by pre-exposure to IL-1band this effect was blocked by 3-O-methylsphingomyelin (3-O-MS), a selective
inhibitor of the ceramide-producing enzyme sphingomyelinase. C2-ceramide, a cell permeable analog of cer-
amide, mimicked IL-1b action suggesting that ceramide may be the second messenger of the proconvulsive
effect of IL-1b. The seizure exacerbating effects of either IL-1b or C2-ceramide were dependent on activation
of the Src family of tyrosine kinases since they were prevented by CGP76030, an inhibitor of this enzyme
family. The proconvulsive IL-1b effect was associated with increased T yr
418 phosphorylation of Src-family of
kinases indicative of its activation, and T yr
1472 phosphorylation of one of its substrate, the NR2B subunit of the
N-methyl-D-aspartate receptor, which were prevented by 3-O-MS and CGP76030. Finally, the proconvulsive
effect of IL-1b was blocked by ifenprodil, a selective NR2B receptor antagonist. These results indicate that
the proconvulsive actions of IL-1b depend on the activation of a sphingomyelinase- and Src-family of kinases-
dependent pathway in the hippocampus which leads to the phosphorylation of the NR2B subunit, thus highlight-
ing a novel, non-transcriptional mechanism underlying seizure exacerbation in inflammatory conditions.
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Abbreviations: 3-O-MS=3-O-methylsphingomyelin; BSA=bovine serum albumin; NMDA=N-methyl-D-aspartate;
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type 1; IL-1b=Interle ukin-1b; PBS=phosphate-buffered saline
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Introduction
Prominent inflammatory processes have been described in
epileptogenic brain tissue surgically resected from patients
with chronic drug-resistant epilepsies (Vezzani and Granata,
2005), including clinical cases which do not feature a typical
inflammatory pathophysiology, such as temporal lobe epi-
lepsy and epilepsy-associated with malformations of cortical
development (Crespel et al., 2002; Maldonado et al., 2003;
Ravizza et al., 2006a; Ravizza et al., 2008). Moreover, brain
injuries associated with CNS inflammation lead to the
early occurrence of seizures and can result in epilepsy
(Pitkanen and Sutula, 2002; Vezzani and Granata, 2005).
These observations, together with the clinical evidence
that anti-inflammatory treatments provide seizure control
in some cases of drug-resistant epilepsies (Vezzani and
Granata, 2005), support the possibility that inflammation
in the brain is implicated in the development of seizures.
Accordingly, the induction of brain inflammation by
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 lipopolysaccharide in experimental models has been shown
to increase seizure susceptibility (Sayyah et al., 2003; Heida
and Pittman, 2005; Galic et al., 2008). Experimental studies
also indicate that seizures per se are among the most potent
inducers of cytokines and other downstream mediators of
inflammation in the brain (Vezzani et al., 1999; De Simoni
et al., 2000; Turrin and Rivest, 2004; Vezzani and Granata,
2005; Gorter et al., 2006; Aronica et al., 2007), suggesting
that seizures, upon their occurrence, contribute to perpet-
uate brain inflammation. Immunohistochemical analysis of
epileptogenic areas after induction of seizures in rodents
showed a strong and rapid upregulation of interleukin-1b
(IL-1b) in astrocytes and microglia. Fast onset neuronal
expression of IL-1 receptor type 1 (IL-1R1) was also observed,
followed by upregulation of IL-1R1 in astrocytes (Vezzani
et al., 1999, 2000; Ravizza and Vezzani, 2006; Ravizza et al.,
2008), suggesting that IL-1b mediates functional glio-
neuronal communication during seizures. A similar pattern
of IL-1b and IL-1R1 expression was demonstrated in human
chronic epileptic tissue (Ravizza et al., 2006a, 2008).
Pharmacological studies support a crucial role of the
IL-1b–IL-1R1 signaling in neuronal network hyperexcit-
ability underlying seizures. Thus, intracerebral application
of IL-1b decreases the threshold of seizure induction (Dube ´
et al., 2005; Heida and Pittman, 2005) and prolongs the
frequency and duration of seizures (Vezzani et al., 1999,
2000). In contrast, IL-1Ra, an endogenous IL-1R1 compe-
titive antagonist (Dinarello, 1998), mediates powerful anti-
convulsant effects (De Simoni et al., 2000; Vezzani et al.,
2002), and mice overexpressing the secreted human form of
IL-1Ra in astrocytes exhibit decreased seizure susceptibility
(Vezzani et al., 2000). Importantly, seizures are dramatically
reduced when blocking endogenous IL-1b synthesis by
interleukin-1 converting enzyme (ICE) inhibition, or in
mice with a null mutation of ICE (Ravizza et al., 2006b).
These data indicate that elevated levels of IL-1b in the brain
due to a preexisting inflammatory state or to the occur-
rence of seizures, or both, result in proconvulsive effects.
The effects of IL-1b on seizures have a rapid onset, which
is consistent with activation of fast, non-transcription
dependent pathways that leads to ion channels modifica-
tion. We had previously demonstrated that IL-1b activa-
tion of IL-1R1 in cultured hippocampal neurons induces
Src family of kinases-mediated tyrosine phosphorylation of
N-methyl-D-aspartate (NMDA) receptor NR2B subunit
which is co-expressed with IL-1R1 on pyramidal hippo-
campal neurons (Viviani et al., 2003). This effect facilitates
NMDA receptor-mediated increase in intracellular Ca
2+ in
neurons (Viviani et al., 2003), suggesting that this molec-
ular event may be involved in IL-1b proconvulsive actions.
Ceramide, the intracellular signaling product of sphingo-
myelinases (Kolesnick and Golde, 1994) also alters Ca
2+
currents in neurons through ceramide-activated protein
phosphatases and kinases like Src, which in turn changes
the phosphorylation state of various receptors and ion
channels, including NMDA receptors (Gulbins et al., 1997;
Bock et al., 2003; Salter and Kalia, 2004; Davis et al.,
2006b). In particular, the ceramide-producing enzyme
neutral sphingomyelinase (N-Smase) is activated in mouse
forebrain upon application of IL-1b via the IL-1R1–MyD88
complex (Nalivaeva et al., 2000).
We tested here whether this pathway, which starts with
IL-1b-mediated activation of N-Smase, the production of
ceramide and the subsequent phosphorylation of Src-family
of tyrosine kinases and the target receptor protein NR2B
subunit, mediates the proconvulsive effects of IL-1b. The
detailed understanding of the IL-1b-mediated signaling in
conditions of elevated cytokine levels is instrumental for
understanding the mechanisms underlying seizure exacer-
bation in inflammatory conditions.
Materials and Methods
Experimental animals
Animals were housed at a constant temperature (23 C) and rela-
tive humidity (60%) with free access to food and water and a
fixed 12h light/dark cycle. Procedures involving animals and their
care were conducted in conformity with the institutional guide-
lines that are in compliance with national and international laws
and policies.
Cannula and electrodes implantation
Male C57BL6 mice (60-day-old, 25g, Charles River, Calco, Italy)
were surgically implanted with an injection guide cannula and
recording electrodes under deep Equithesin anestesia and stereo-
taxic guidance (Vezzani et al., 2000; Balosso et al., 2005). Two
nichrome-insulated bipolar depth electrodes (60mm OD) were
implanted bilaterally into the dorsal hippocampus [from bregma
(mm): nose bar 0; anteroposterior –1.9, lateral 1.5 and 1.8 below
dura mater]. A 23-gauge cannula was unilaterally positioned on
top of the dura mater and glued to one of the depth electrodes
for the intrahippocampal infusion of drugs (see below). In some
mice, an additional guide cannula was positioned on dura mater
ipsilateral to the hippocampal cannula for intracerebroventric-
ular (icv) injection of drugs [from bregma (mm): nose bar 0;
anteroposterior 0.0, lateral 1.0 and 3.0 below dura mater]. The
electrodes were connected to a multipin socket and, together with
the cannula of injection, secured to the skull by acrylic dental
cement. The correct position of the electrodes and injection needle
was evaluated in the sections used for immunohistochemical
analysis of brain tissue (see below).
Pharmacological treatments
Intracerebral injection of drugs in freely moving mice have been
previously described (Vezzani et al., 2000; Balosso et al., 2005).
Kainic acid (7ng/0.5ml; Sigma, Saint Louis, MI, USA) was
dissolved in 0.1M phosphate-buffered saline (PBS, pH 7.4) and
injected unilaterally in the dorsal hippocampus by using a needle
protruding 1.8mm from the bottom of the guide cannula. This
dose of kainic acid was proven to induce EEG ictal episodes and
spiking activity in the hippocampus in 100% of mice without
mortality (Balosso et al., 2005).
Human recombinant (hr)IL-1b (R&D System, Minneapolis,
USA) was dissolved in 0.1M PBS supplemented with 0.1%
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 bovine serum albumin (BSA) and injected intrahippocampally
(1ng/0.5ml) 10min before kainic acid. This is the same dose
causing proconvulsive effects in kainate-injected rats (Vezzani
et al., 1999, 2002).
C2-ceramide, a membrane-permeable ceramide analogue, and
dihydroceramide, the biologically inactive form of C2-ceramide
(Sigma) (Obeid et al., 1993) were dissolved in 10% dimethyl-
sulfoxide (DMSO) in PBS and injected intrahippocampally
(0.25–1.0–2.0mg in 0.5ml), 10min before kainic acid.
3-O-Methylsphingomyelin (3-O-MS, N-Smase inhibitor;
BioMol Research Laboratories Inc., PA, USA) (Zeng et al.,
2005; Tsakiri et al., 2008) was dissolved in 10% DMSO in PBS
and injected intrahippocampally (3mg/0.5ml) or ICV (15mg/1ml),
20min before kainic acid. These doses were shown to block the
rapid phase of febrile response to IL-1b after injection into the
mouse preoptic area/anterior hypothalamus (pilot study; see
Sanchez-Alavez et al., 2006).
CGP76030, a selective Src-family of tyrosine kinase inhibitor
which binds to the catalytic SH1 domain, thus preventing substrate
phosphorylation (Susa et al., 2000; Susa et al., 2005; Rucci et al.,
2006) was provided as a research tool by Novartis AG, Basel,
Switzerland. It was dissolved in 2% DMSO in PBS and injected
intrahippocampally (65ng/0.5ml) or icv (130ng/1ml), 20min
before kainic acid. The dosage of CGP76030 corresponds to the
oneachieved in mouse brain after oraladministration of 30mmol/kg,
as assessed measuring its brain/plasma ratio at 1 and 3h, reaching
a highest ratio at 3h. This dose blocked the electrophysiological
effects of IL-1b on the activity of warm-sensitive hypothalamic
neurons in vivo (pilot study; see also Sanchez-Alavez et al., 2006).
Ifenprodil [NR2B-selective NMDA antagonist (Chenard and
Menniti, 1999), Sigma] was dissolved in 5% DMSO with 9%
Tween 80 in PBS and injected intraperitoneally (1mg/kg), 15min
before kainic acid. We choose this dose since it was shown to
block NR2B receptors in vivo during tPA facilitation of ethanol
withdrawal seizures, although not affecting seizures per se (Pawlak
et al., 2005).
Control mice were injected with the corresponding volume of
vehicles before kainic acid. Pharmacological experiments were
carried between 9.00 am and 2.00pm.
Seizures assessment and quantification
EEG seizures induced by intrahippocampal injection of kainic acid
in mice have been extensively described (Balosso et al., 2005).
Briefly, a 30min recording was done before kainic acid injection
to assess the basal EEG pattern and for 180min thereafter. At least
a 30min recording similar to baseline was required before ending
the experiment. Ictal episodes are characterized by high-frequency
and/or multispike complexes and/or high-voltage synchronized
spikes simultaneously occurring in the injected and contralateral
hippocampi. Spiking activity is typically observed between seizures
and after seizures subside. The EEG recording of each animal was
analysed visually by two independent investigators unaware of the
treatments to detect any activity different from baseline. Seizure
activity was quantified by reckoning the time elapsed from kainic
acid injection to the occurrence of the first EEG seizure (onset)
and the total number and total duration of seizures (reckoned by
summing up the duration of every ictal episode during the EEG
recording period). Seizures occurred with an average latency of
about 10min from kainic acid injection, then recurred for about
90min from their onset. Interictal activity was reckoned by sum-
ming up the time spent in EEG spiking.
Immunocytochemistry
At the end of the EEG analysis, mice injected with kainic acid
(n=5) and their controls (n=5), were deeply anaesthetized using
Equithesin and perfused via ascending aorta with 50mM cold
PBS, pH 7.4 followed by chilled 4% paraformaldehyde in 0.1M
PBS. The brains were post-fixed for 90min at 4 C, and then
transferred to 20% sucrose in PBS for 24h at 4 C. The brains were
rapidly frozen in –50 C isopentane for 3min and stored at –80 C
until assayed. Serial cryostat coronal sections (40mm) were cut
from all brains throughout the septo-temporal extension of the
hippocampus (Franklin and Paxinos, 1997) and collected in 0.1M
PBS. Primary and secondary antibodies and experimental proce-
dures were chosen to determine a specific immunohistochemical
signal of the protein of interest in rodent brain slices (Ravizza and
Vezzani, 2006; Ravizza et al., 2008).
IL-1. Slices were incubated at 4 C for 10min in 70% methanol
and 2% H2O2 in Tris–HCl-buffered saline (TBS, pH 7.4) followed
by 30min incubation in 10% foetal calf serum (FCS) in 1% Triton
X-100 in TBS. Then, slices were incubated overnight with the
primary antibody against IL-1b (1:200, Santa Cruz Bio., CA, USA)
at 4 C in 10% FCS in 1% Triton X-100 in TBS. Immunoreactivity
was tested by the avidin-biotin-peroxidase technique (Vector Labs,
USA), the sections were reacted using diaminobenzydine (DAB)
and the signal was amplified by nickel ammonium.
IL-1R1. IL-1R1 immunostaining was carried out as previously
described (Ravizza and Vezzani, 2006). Briefly, sections were
incubated at 4 C for 10min in 0.3% H2O2 in 0.3% Triton X-100
in PBS. After three 5min washes in 0.3% Triton X-100 in PBS,
slices were incubated at 4 C for 60min in 10% FCS in 0.3%
Triton X-100 in PBS. Then, slices were incubated with the primary
antibody against IL-1R1 (6mg/ml, R&D System) for 72h at 4 Ci n
4% FCS in 0.3% Triton X-100 in PBS. Immunorectivity was tested
as described for IL-1b.
Double-immunostaining
Two brain slices in each mouse brain for each cell type marker
were randomly chosen to identify the cells expressing IL-1b or
IL-1R1. After incubation with the primary IL-1b and IL-1R1
antibodies, slices were incubated in biotinylated secondary
anti-goat and anti-hamster antibodies respectively (1:200, Vector
Labs), then in streptavidin–HRP and the signal was revealed with
tyramide conjugated to Fluorescein using TSA amplification kit
(NEN Life Science Products, Boston, MA, USA). Sections were
subsequently incubated with the following primary antibodies:
mouse anti-glial fibrillary acidic protein (1:2500; GFAP, Chemi-
con, Temecula, CA, USA), a selective marker of astrocytes, or
rat anti-mouse CD11b (1:1000; MAC-1, Serotec, Oxford, UK),
a marker of microglia-like cells, or mouse anti-neuronal specific
nuclear protein (1:1000; NeuN, Chemicon), a selective neuronal
marker. Fluorescence was detected using anti-mouse or anti-rat
secondary antibody conjugated with Alexa546 (Molecular Probes,
Leiden, The Netherlands). Slide-mounted sections were examined
with an Olympus Fluorview laser scanning confocal microscope
(microscope BX61 and confocal system FV500; Hamburg, Germany)
using dual excitation of 488nm (Laser Ar) and 546nm (Laser
He–Ne green) for Fluorescein and Alexa546, respectively. The
emission of fluorescent probes was collected on separate detectors.
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 To eliminate the possibility of bleed-through between channels, the
sections were scanned in a sequential mode.
Evaluation of neuronal damage
Neuronal loss was evaluated using Nissl-stained slices as pre-
viously described (Hoffman et al., 2003). A subset of mice treated
with kainic acid, or ceramide+kainate, or IL-1b+kainate and
their respective vehicle- injected controls, were killed one week
after treatment by transcardial perfusion as described above (n=5
mice in each experimental group). Serial cryostat sections (40mm)
were cut coronally from plate 41 to 50 according to Franklin
and Paxinos (1997), collected on slides and Nissl stained. Two
sections in each brain were analysed, namely at –1.46mm (corre-
sponding to plate 43) and –2.06mm (corresponding to plate 48)
from bregma.
In each section, neuronal cell loss was quantified by measuring
the area occupied by Nissl-stained neurons in CA3 pyramidal
cell layers (Hoffman et al., 2003). An image of the whole hippo-
campus was captured with a 4  objective using an Olympus light
microscope (BX61; Hamburg, Germany) connected to a Color-
View digital camera (Olympus). Using an AnalySIS Image Pro-
cessing software (Soft Imaging System, Olympus), we divided the
areas of interest in non-overlapping fields (each of 700mm
width 400mm high) using a 20  magnification, and in these
fields we measured the area (in mm
2) occupied by Nissl-stained
neurons. By summing up these values, we determined the total
area in CA3 occupied by Nissl-stained neurons which reflects
neuronal density in each region. The quantification of neuronal
loss was performed by two investigators blind to the identification
code of the samples.
Western blot
Different groups of mice (n=10–14 in each group) were
implanted with electrodes and cannula as described before and
injected with hrIL-1b, kainic acid, or their combination   3-O-
MS or CGP76030 (see before for injection protocol). Control mice
(n=14) were implanted with electrodes and cannula and injected
with the corresponding vehicles of the various treatments at the
appropriate time interval. One hour after the onset of EEG sei-
zures, experimental mice and their controls were decapitated.
The injected dorsal hippocampus was dissected out at 4 C and two
hippocampi obtained from different mice within the same experi-
mental group were pooled and homogenized in 20mM Tris–HCl
buffer (pH 7.4) containing 1mM EDTA, 5mM EGTA, 1mM
Na-vanadate, 2mg/ml aprotinin, 1mg/ml pepstatin, 2mg/ml leupeptin
(30mg tissue/150ml homogenization buffer), thus obtaining five
to seven individual samples in the various treatment groups. Total
proteins (70mg per lane; Bio-Rad Protein Assay) were separated
using SDS-PAGE, 10% acrylamide and each sample was run
in duplicate. Proteins were transferred to Hybond nitrocellulose
membranes by electroblotting. For immunoblotting, we used anti-
pTyr
418-Src which is located in the catalytic domain therefore
indicative of Src-family of tyrosine kinases activation (1:750; Sigma)
or anti-pTyr
1472-NR2B (1:1000; Affinity Bioreagents Golden, CO,
USA) rabbit polyclonal antibodies. Total NR2B levels were assessed
using goat polyclonal anti-NR2B antibody (1:1000; Santa Cruz).
Immunoreactivity was visualized with enhanced chemiluminescence
(ECL, Amersham, UK) using peroxydase-conjugated goat anti-
rabbit (1:2000; Sigma) or rabbit anti-goat (1:10000; Sigma) IgGs
as secondary antibodies. Densitometric analysis of immunoblots
was done to quantify the changes in protein levels (AIS image
analyzer, Imaging Research Inc., Ontario, Canada) using film
exposures with maximal signals below the photographic saturation
point. Optical density values in each sample were normalized using
the corresponding amount of b-actin.
Statistical analysis of data
Data are the mean SEM (n=number of individual samples).
The effects of treatments were analysed by two-way ANOVA
followed by Tukey or Kruskal–Wallis test, or by Student t-test.
Data reporting quantification of cell loss or depicted in Figs 2
and 3 are expressed as % of vehicle-injected mice; however,
statistical analysis was carried out using absolute values.
Results
Seizure-mediated induction of IL-1b
and IL-1R1 in the mouse hippocampus
Immunohistochemical analysis of hippocampal sections 3h
after intrahippocampal injection of kainic acid, showed
increased IL-1b immunoreactivity in astrocytes (Fig. 1B)
while IL-1R1 was enhanced both in neurons and astrocytes
(Fig. 1D); this activation involved the dorsal and temporal
poles of the hippocampus bilaterally. This is the first evidence
of increased IL-1b and IL-1R1 in mice after kainate-induced
seizures which is in accordance with our previous findings
showing induction of IL-1b and IL-1R1 by chemically- or
electrically-induced seizures in rats (Vezzani et al., 1999,
Ravizza and Vezzani, 2006; Ravizza et al., 2008) or bicucul-
line-induced seizures in mice (Vezzani et al., 2000). IL-1b and
Fig. 1 IL-1band IL-1R1expression in the mouse hippocampus after
kainic acid-induced seizures.Representative photomicrographs
of IL-1b (A^B)a n dI L - 1 R 1( C^D) immunoreactivity in the CA3
area of the hippocampus, 3h after seizures induced by intra-
hippocampal injection of kainic acid (7ng/0.5ml; B and D)a n d
in vehicle-injected C57BL6 mice (A,C). IL-1b (A)a n dI L - 1 R 1
(C) immunostaining was not detectable in control hippocampus.
After seizures,IL-1bimmunoreactivityis stronglyenhancedin
GFAP-positiveastrocytes(B, yellow signal in inset); IL-1R1staining
wasenhancedbothinneurons(D, yellow signalin d1)andastrocytes
(D, yellow signalin d2). Scale bar: A^D100 mm;insets,25mm.
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 IL-1R1 (Fig. 1A and C) were not detectable in control hippo-
campus, as previously shown (Vezzani et al., 1999, 2000;
Ravizza and Vezzani, 2006; Ravizza et al., 2008).
N-Smase-Src kinase-NR2B pathway
mediates the proconvulsive activity of IL-1b
3-O-MS
We established the role of N-Smase in the proconvulsive
effect of IL-1b using the selective N-Smase inhibitor 3-O-MS
(Zeng et al., 2005; Tsakiri et al., 2008) (Table 1). The intra-
hippocampal injection of hrIL-1b, 10min before kainate,
increased by  1.8-fold the number of seizures and by  2-fold
their duration as compared with vehicle-treated mice
(P50.01; Table 1). Three micrograms of 3-O-MS blocked
the proconvulsive effect of hrIL-1b when injected into the
hippocampus, 10min before the cytokine (i.e. 20min before
kainate) since it abolished the increase in the number of
seizures [F(1,62)=2.2; P50.05] and time spent in ictal
activity [F(1,62)=5.9; P50.01 by two-way ANOVA) induced
by hrIL-1b. The latency to the first seizure or the time spent
in interictal activity were not affected by these treatments.
3-O-MS injected intrahippocampally (3mg/0.5ml) (Table 1)
or icv (15mg/1ml) (data not shown) 20min before kainic
acid, did not affect seizure parameters; higher doses could
not be used because of the limit of solubility of this
compound in the volume of injection.
C2-ceramide
Ceramide is produced by N-Smase acting on membrane
sphingomyelin and this pathway is rapidly activated in
mouse forebrain by IL-1b via IL-1R1 (Nalivaeva et al.,
2000). Intrahippocampal injection of C2-ceramide, the cell-
penetrating analog of ceramide, 10min before kainic acid,
dose-dependently enhanced the number of seizures and
their duration (Fig. 2) without changing the time to onset
of seizures and the spiking activity (Table 2). No effect on
seizures was observed using 0.25mg C2-ceramide, 1mg sig-
nificantly increased seizures duration by  2-fold (P50.05)
while 2mg significantly increased the number of seizures by
2-fold and their duration by 2.5-fold on average (P50.01)
versus mice injected with dihydroceramide, a membrane-
impermeable ceramide analog (Fig. 2A; see Table 2). Thus,
C2-ceramide mimics IL-1b proconvulsive effects inducing
also a similar EEG pattern of seizures (Fig. 2B). IL-1b or
C2-ceramide alone did not induce seizures.
Either C2-ceramide or IL-1b did not affect the pattern
or extent of neuronal cell loss induced by kainate in mice,
which consists of degeneration of CA3 pyramidal neurons in
the injected hippocampus as assessed by Nissl staining in a
subset of mice (n=5 each group) killed 7 days after seizure
induction [–1.46mm from bregma; data are expressed as
percentage of vehicle (n=5); ‘vehicle’, 100 3.7, ‘kainate’,
86.2 5.4; ‘ceramide+kainate’, 81.1 8.1; ‘IL-1b+kainate’,
81.5 7.0 (P50.05 for each treatment groups versus vehicle);
–2.06mm from bregma; ‘vehicle’, 100 2.0, ‘kainate’,
67.1 9.7; ‘ceramide+kainate’, 69.5 9.0; ‘IL-1b+kainate’,
63.3 5.4 (P50.05 for each treatment groups versus vehicle)].
CGP76030
Tables 1 and 2 show the effect of intrahippocampal
injection of the selective inhibitor of Src-family of tyrosine
kinase activity, CGP76030 (Susa et al., 2000, 2005; Rucci
et al., 2006), on the proconvulsant effect of hrIL-1b
(Table 1) and C2-ceramide (Table 2). CGP76030 (65ng/
0.5ml) injected 20min before kainate, significantly pre-
vented the 2-fold increase in the number of seizures
induced by IL-1b [F(1,63)=5.9; P50.05] or C2-ceramide
[F(1,28)=23.9; P50.01] and in the time spent in
ictal activity induced by IL-1b [F(1,63)=13.3; P50.01] or
C2-ceramide [F(1,28)=30.9; P50.01 by two-way ANOVA].
Intrahippocampal CGP76030 did not affect seizures per se;
however, when 130ng/1ml CGP76030 was injected alone
icv 20min before kainate, the number and the duration of
Table 1 Effect of inhibition of the N-Smase-Src-NR2B pathway on the proconvulsive effects of IL-1b
Dose Onset (min) Number of seizures Time in ictal activity (min) Time in spikes (min)
Vehicle ^ 8.7  0.5 9.0  1.0 5.6   0.5 48.0  3.8
hrIL-1b 1ng, i.h. 7 .6 0.4 16.0  2.0
   11.8  1.1
   50.0 3.7
3-O-MS 3mg, i.h. 8.6 1.0 7.0  1.0 4.9   0.6 43.9  6.6
3-O-MS + hrIL-1b 9.9  2.1 8.0 1.0
y 5.2 0.6
yy 48.5  4.6
CGP076030 65 ng, i.h. 8.1  1.0 10.0  2.0 6.3 1.1 53.3  7. 5
CGP76030+hrIL-1b 8.8  0.9 7.0  1.0
y 3.8   0.6
yy 47 .4  4.7
Ifenprodil 1mg, i.p. 9.2  2.1 8.0 1.0 6.4  1.3 42.9 6.6
Ifenprodil+hrIL-1b 8.9 1.7 9.0  1.0
y 5.0   0.5
yy 59.4   4.2
Data are the mean SE (n=mice in each experimental group).Vehicle (n=23 mice) represents C57BL6 mice treated with the corre-
sponding vehicles of the various treatments at the appropriate times before kainic acid application; since these mice did not differ in
seizure parameters they were pooled in a single control group. hrIL-1b (n=28) are mice injected in the hippocampus (i.h.) with this
cytokine (1ng/0.5ml) 10min after receiving the corresponding vehicles of the various treatments, then they were treated10min later
with kainic acid (7ng/0.5ml). Since these mice did not differ in seizure parameters they were pooled in a single group. 3-O-MS, CGP76030
or ifenprodil (n=7^11) were injected alone or with hrIL-1bbefore kanic acid injection (see Methods for details).
  P50.01 versus vehicle;
yP50.05,
yyP50.01 versus hrIL-1bby two-way ANOVA followed byTukey’s test [F(DF) for each treatment group are reported in the
Result section].
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 seizures were decreased by  1.8- and 2-fold, respectively,
as compared with vehicle-treated mice [number of seizures:
vehicle, n=8, 16.0 2.0; CGP, n=8, 9.0 1; P50.01; time
in ictal activity (min): vehicle, 9.9 0.5; CGP, 4.8 0.4;
P50.01 by Student’s t-test].
Ifenprodil
Ifenprodil (1mg/kg), a NR2B-specific NMDA antagonist
(Chenard and Menniti, 1999), injected 5min before
hrIL-1b blocked the cytokine-mediated increase in the
number [F(1,61)=2.2; P50.05] and total time in seizures
[F(1,61)=9.0; P50.01 versus hrIL-1b by two-way
ANOVA] (Table 1). This dose of ifenprodil did not affect
seizures per se (Pawlak et al., 2005), although higher doses
are known to provide anticonvulsive effects (Kohl and
Dannhardt, 2001; Yen et al., 2004).
Effect of pharmacological treatments
on Src-family of tyrosine kinases activation
and NR2B phosphorylation
We assessed by western blot analysis of hippocampal homo-
genates, the level of tyrosine phosphorylated (p) forms of
Src-family of kinases and the NR2B subunit of NMDA
receptor, 60min after seizures onset in kainate IL-1b
injected mice, as well as in mice receiving IL-1b alone
(Fig. 3). Densitometric analysis of the specific protein bands
showed that either hrIL-1b alone (no seizures) or seizures
per se increased phosphorylation (p) of Src-family of kinases
on Tyr
418 in the catalytic domain denoting their activation
(Papp et al., 2008), by 40% on average as compared to
vehicle-treated mice (P50.05 and P50.01, respectevely)
while in the same hippocampi the Tyr
1472 phosphorylation
Fig. 2 EffectofC2-ceramideonseizures.(A)Bargramsrepresentthemean SE (n=12).Dihydroceramide,theinactiveanalogueofceramide,
(2mg/0.5 ml) or C2-ceramide (the cell-permeable analogue of ceramide; 0.25^1.0^2.0mg/0.5ml) wereinjectedintrahippocampally,10min
beforekainic acid.Significantincreasesinseizureparameterswereobservedat1and2mgC2-ceramide.
 P50.05;
  P50.01versus dihydro-
ceramidebyonewayANOVAfollowedbyTukey test.(B)RepresentativeEEGtracingsoffreelymovingC57BL6miceinjectedunilaterallyin
thehippocampuswithkainic acid IL-1b(1ng/0.5 ml) or C2-ceramide (2mg/0.5 ml).Treatments or vehiclesweregiven10minbeforekainic acid.
(a) Baselinerecordingbeforekainic acidinjection; arrowheadsin (b) and (c) includerepresentativeictal episodesrecordedin the EEGduring
90min after kainic acidinjection IL-1bor C2-ceramide; tracingsin (d) depict spiking activityin the EEGafter termination of seizures.Either
IL-1borC2-ceramidealonedidnotinduceseizures.RHPandLHParerightandleft(injected)hippocampus,respectively.
Table 2 Effect of inhibition of Src-family of tyrosine kinases on the proconvulsive effects of C2-ceramide
Dose Onset (min) Number of seizures Time in ictal activity (min) Time in spikes (min)
Dihydroceramide 2 mg8 . 6   0.7 8.0  1.0 5.4   0.5 44.0  3.4
C2-Ceramide 2mg8 . 9  1.4 18.0  2.0
   13.4  1.0
   51.1  3.7
CGP076030 65 ng 8.1  1.0 10.0  2.0 6.3 1.1 53.3  7. 5
CGP076030 + C2-Ceramide 8.4  1.6 8.0  1.0
yy 5.5   0.4
yy 45.0 3.3
Data are the mean SE (n=7^9 mice in each experimental group).C57BL6 mice were injected intrahippocampally with C2-ceramide
(2mg/0.5 ml) or CGP076030 (65ng/0.5ml), or their combination before intrahippocampal kainic acid injection (7ng/0.5ml).
  P50.01
versus the inactive analog dihydroceramide;
yyP50.01versus C2-ceramide by two-way ANOVA followed byTukey’s test [F(DF) for each
treatment group are reported in the Results section].
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 of the NR2B form, causing upregulation of channel gating
properties (Salter and Kaila, 2004), was increased by 26% and
47% on average, respectively (P50.01). When hrIL-1b was
coinjected with kainic acid, thus producing proconvulsive
effects, (p)Src and (p)NR2B levels were increased by 127%
and 82% respectively as compared to vehicle-treated mice
(P50.01), denoting additive effects of the single treatments.
We also evaluated whether inhibition of N-Smase or
Src-family of kinases activity affects the increased (p)Src
and (p)NR2B levels observed in proconvulsive conditions.
3-O-MS or CGP76030at the doses which blocked the pro-
convulsive effects of IL-1b, reversed NR2B phosphorylation
by reducing (p)NR2B to the levels of vehicle-injected mice
[3-O-MS: F(1,17)=21.9; P50.01; CGP76030: F(1,17)=10.7;
P50.01]. In IL-1b+kainate-treated mice, inhibition of
N-Smase by 3-O-MS similarly reversed Src-family of kinases
phosphorylation [F(1,17)=30.5; P50.01], which was not
affected by CGP76030 treatment. 3-O-MS or CGP76030
alone did not change the basal level of (p)Src and (p)NR2B.
The total levels of NR2B were not changed by the various
treatments (not shown).
Discussion
This study shows a novel IL-1b-IL-1R1 activated cell sig-
naling that mediates the proconvulsive actions of IL-1b in
the mouse hippocampus. IL-1b is a pluripotent proinflam-
matory cytokine which binds to IL-1R1, a Toll receptor
family member, and induces via an NFkB-dependent mech-
anism, the transcription of various genes encoding several
downstream mediators of inflammation, including IL-6 or
TNF-a, inducible NO and COX-2 (Dinarello, 2004); the
time scale of these effects is included between 30 and
90min. The activation of this Toll-like pathway requires
transcription and translation of the encoded proteins with
their subsequent release, therefore it is unlikely to account
for the recently described rapid effects of IL-1b on NMDA-
dependent neuronal Ca
2+ influx and seizure activity
(Vezzani et al., 1999, 2000; Viviani et al., 2003; Ravizza
et al., 2006b). This consideration raises the hypothesis that
the proconvulsant action of IL-1b involves an additional,
rapid, non-transcriptional intracellular neuronal pathway
leading to fast changes in ion channels. Previous reports
have shown neuronal effects of IL-1b in hippocampal and
hypothalamic neurons involving synaptic plasticity and
thermoregulation which also appear to be independent of
transcriptional events (Davis et al., 2006b; Sanchez-Alavez
et al., 2006; Pickering and O’Connor, 2007; Viviani et al.,
2007). In particular, the activation of the ‘IL-1b-N-Smase-Src
kinase pathway’ has been shown to mediate the ‘fast actions
of IL-1b’ on preoptical/anterior warm sensitive hypothalamic
neurons underlying the rapid phase of the febrile response
to IL-1b (Sanchez-Alavez et al., 2006). When studying these
IL-1b effects in hypothalamic neurons in vivo and in vitro,
we found that the effects of IL-1b can be mimicked by
C2-ceramide, and that inhibitors of N-Smase in the brain
lower or prevent the response to IL-1b (Sanchez-Alavez
et al., 2006). Furthermore, the formed ceramide activates
the Src-family of tyrosine kinases in hypothalamic neurons,
but not in glia (Davis et al., 2006a, b).
We show here, using a detailed pharmacological approach,
that inhibition of N-Smase using 3-O-MS blocks the increase
in the frequency and duration of seizures induced by IL-1b
and that C2-ceramide faithfully mimics the IL-1b effect on
seizures, thus suggesting that the activation of the N-Smase-
ceramide pathway mediates the proconvulsive activity of this
cytokine. To elucidate the downstream events which follow
N-Smase activation, we addressed the possible involvement
Fig. 3 IL-1band seizure induced tyrosine phosphorylation of Src-
family of kinases and the NR2B subunit of the NMDA receptor:
effect of pharmacological treatments. Bargrams show densitome-
try analysis of the Src kinases and NR2B bands corresponding to
their phosphorylated (p) forms (Src-Tyr
418;N R 2 B - T y r
1472)i nt h e
various experimental groups, 60min after the onset of kainate-
induced seizures ( 70min after kainate injection), as assessed by
western blot analysis of hippocampal homogenates.Vehicle- or
IL-1balone- treated mice were killed 70min after the injection.
Data (means SE, n=5^7) are optical density (O.D.) values of
the relevant bands (as depicted in the representative western blot),
divided by the corresponding b-actin value (internal standard).
Data are expressed as percentage of values measured in corre-
sponding vehicle-treated mice. IL-1b (1ng/0.5 ml) was injected alone
or 10min before kainic acid; 3-O-MS (3mg/0.5 ml) and CGP76030
(65ng/0.5ml) were injected 20min before kainic acid (i.e.10min
before IL-1b). 3-O-MS or CGP76030 alone did not change protein
phosphorylation levels as compared to vehicle-injected mice;
total NR2B levels were not changed by the various treatments
(not shown).
 P50.05;
  P50.01 versus vehicle;
##P50.01 versus
3-O-MS+IL-1+KA and versus CGP76030+IL-1+KA (for pNR2B
only) by two-way ANOVA followed by Kruskal^Wallis test.
Representative western blot bands corresponding to the
specific proteins are depicted in B.
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 of the Src-family of kinases. Thus, this family of enzymes is
known to be activated by ceramide (Kolesnick and Golde,
1994; Saklatvala, 1995), and a similar cascade of events was
previosly shown to mediate the electrophysiological effects of
IL-1b on the activity of warm-sensitive hypothalamic neurons
(Davis et al., 2006b; Sanchez-Alavez et al., 2006). Our data
show that the inhibition of the Src-family of kinases activity
prevents the IL-1b and C2-ceramide proconvulsive effects
similarly, thus suggesting that Src-family of tyrosine kinases
activation is a downstream event subsequent to IL-1b
activation of N-Smase. This possibility is also supported by
the reversal of IL-1b-induced tyrosine phosphorylation of
Src-family of kinases during seizures using the N-Smase
inhibitor.
Src-family of tyrosine kinases is abundantly expressed in
neurons, and one main function of the activated forms of
two members of this family, namely c-Src and Fyn, is to
upregulate the activity of NMDA receptors via Tyr
1472-
phosphorylation of the NR2B subunit (Ali and Salter,
2001). We found that ifenprodil, a selective antagonist of
NMDA receptors containing the NR2B subunit, prevented
the proconvulsive effects of IL-1b, thus indicating that this
subunit is critically involved in IL-1b action on seizures.
Our previous findings in primary cultures of hippocampal
neurons showed that IL-1b induces the Tyr
1472-phosphor-
ylation of the NR2B subunit via Src-family of kinases acti-
vation (Viviani et al., 2003), therefore we assessed whether
these events occurred in vivo when seizures were poten-
tiated by IL-1b. The levels of the phosphorylated forms
of Src-family of kinases and the NR2B subunit in the
hippocampus were indeed enhanced by IL-1b or seizures,
and these effects were additive when seizures were
increased by IL-1b. Moreover, NR2B Tyr
1472-phosphoryla-
tion induced in proconvulsive conditions was reversed to
baseline level in mice treated with N-Smase and Src-family
of kinases inhibitors, thus supporting the involvement
of these enzymes in the activation of this receptor subunit
(Yu et al., 1997). Tyr
1472-phosphorylation of the NR2B
subunit promotes Ca
2+ influx into neurons (Yu et al., 1997;
Viviani et al., 2003), thus resulting in potentiation of
NMDA function which is pivotal for evoking neuronal
hyperexcitability (Meador, 2007). This molecular event may
be the ultimate step of this novel ‘IL-1b-N-Smase-Src
kinase’ pathway responsible for the increased neuronal
excitability and subsequent proconvulsive effects of this
cytokine. Although CGP76030 selectively inhibits Src-family
of tyrosine kinases activation, and it was shown to have
higher affinity for c-Src versus other Src-family of tyrosine
kinase members (Susa et al., 2000, 2005), no data about the
inhibitor IC50 on Fyn activity are available, therefore both
c-Src and Fyn may be involved in the IL-1b signaling
underlying its proconvulsive effects. The possible specific
involvement of c-Src versus Fyn should await the possibility
to unequivocally distinguish the involvement of these two
kinase activities using pharmacological approaches which
are not yet available.
Interestingly, Src-family of tyrosine kinases appears to
contribute to seizures also in the absence of proinflamma-
tory conditions since Src-family of kinases inhibition per se
after icv, but not intrahippocampal injection of CGP76030,
reduced seizures number and duration in mice. We could
not affect seizures by inhibiting the activity of N-Smase
using 3-O-MS either intrahippocampally or icv injected.
The lack of effect of intrahippocampal application of these
drugs on kainate-induced seizures may be due to the
local spread of the inhibitors around the injection site as
opposed to seizures-induced IL-1b expression throughout
the whole hippocampus. Moreover, we should also consider
the possibility that the dose of 3-O-MS allowed to be
injected by the limited solubility of this compound is not
enough to protect from kainate seizures.
Although hippocampal EEG seizure activity was increased
by IL-1b or C2-ceramide, cell death in the hippocampus
was not affected. This observation indicates that the increase
in seizures was insufficient to induced additional cell loss
which was restricted in this model to CA3 pyramidal cells
in the injected hippocampus. Moreover, CA3 degeneration
has been reported to depend on a direct neurotoxic action
of kainate rather than on seizures per se (Fariello et al, 1989;
Jarrard, 2002), therefore suggesting that kainate-induced
cell loss in this model is insensitive to the proneurotoxic
actions of IL-1b.
The relevance of our findings for the etiopathogenesis
of seizures is based on clinical and experimental evidence
showing that the IL-1b system is activated in chronic
human epilepsy (Vezzani and Granata, 2005; Ravizza et al.,
2006a, 2008) and that anti-IL-1b pharmacological treat-
ments result in powerful anticonvulsant effects (De Simoni
et al., 2000; Vezzani et al., 2000, 2002; Ravizza et al.,
2006b). Moreover, several brain injuries in humans are
associated with brain inflammation, result in early occur-
rence of seizures and present a high risk of developing
epilepsy (Pitkanen and Sutula, 2002; Vezzani and Granata,
2005). Therefore, the elucidation of this novel IL-1b-
activated pathway in the hippocampus adds important
insights into the mechanisms of ictogenesis in inflammatory
conditions and may allow the development of innovative
strategies to block the activation of IL-1b signaling in
disease conditions, thus highlighting potential new targets
of therapeutic intervention.
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